Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + tamoxifen
- Development stage
- Preclinical
- Lead developer
- Shenyang Pharmaceutical University
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Docetaxel is a taxoid antineoplastic agent that binds to microtubules, stabilizing them and preventing cell division, leading to cancer cell death. Tamoxifen is a selective estrogen receptor modulator (SERM) that acts as an antagonist in breast tissue, blocking estrogen signaling in hormone receptor-positive breast cancer cells. The combination of docetaxel and tamoxifen has been investigated for the treatment of breast cancer; however, when used together in standard formulations, they can exhibit antagonism due to differing metabolic pathways. Novel nanoparticle-based co-delivery systems have been developed to overcome this antagonism by controlling drug release and improving tumor targeting[1][2].
- Other names
- DTX + TMXdocetaxel and tamoxifen
02
Targets
TUBB (Tubulin (alpha and beta subunits))ESR1 (ERα)
Beyond the preview
Go deeper on docetaxel + tamoxifen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + tamoxifen.